CalciMedica, Inc. (CALC)
OTCMKTS: CALC · Delayed Price · USD
4.160
0.00 (0.00%)
Mar 28, 2024, 4:00 PM EDT - Market closed
Company Description
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs.
Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases.
Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury.
The company is based in La Jolla, California.
CalciMedica, Inc.
Country | Canada |
Founded | 2011 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 14 |
CEO | Dr. A. Rachel Leheny Ph.D. |
Contact Details
Address: 505 Coast Boulevard South, Suite 307 La Jolla, California 92037 United States | |
Phone | 858-952-5500 |
Website | calcimedica.com |
Stock Details
Ticker Symbol | CALC |
Exchange | OTCMKTS |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001534133 |
ISIN Number | US38942Q2021 |
Employer ID | 45-2120079 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. A. Rachel Leheny Ph.D. | Chief Executive Officer and Director |
Eric W. Roberts | Chief Business Officer and Vice Chairman of the Board |
Michael J. Dunn MBA | President and Chief Operating Officer |
Dr. Anjana Rao Ph.D. | Co-Founder and Scientific Advisor |
Dr. Patrick Hogan Ph.D. | Co-Founder and Scientific Advisor |
Dr. Stefan Feske M.D. | Co-Founder and Scientific Advisor |
Dr. Kenneth A. Stauderman Ph.D. | Co-Founder and Chief Scientific Officer |
Daniel E. Geffken M.B.A. | Interim Chief Financial Officer |
Cindy Reiedenberg | Accountant |
John M. Dunn J.D. | General Counsel |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 28, 2024 | 8-K | Current Report |
Feb 13, 2024 | 8-K | Current Report |
Feb 9, 2024 | EFFECT | Notice of Effectiveness |
Feb 8, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Feb 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 6, 2024 | UPLOAD | Filing |
Feb 5, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Feb 1, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Feb 1, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |